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Abstract     28 
Improving our understanding of the mechanisms controlling the corpus luteum (CL) and 29 
its role in regulating the reproductive cycle should lead to improvements in the 30 
sustainability of today’s global animal industry. The corpus luteum (CL) is a transient 31 
endocrine organ composed of a heterogeneous mixture steroidogenic, endothelial and 32 
immune cells, and it is becoming clear that immune mechanisms play a key role in CL 33 
regulation especially in luteolysis. Toll-like receptors (TLR) mediate innate immune 34 
mechanisms via the production of pro-inflammatory cytokines, especially within various 35 
tissues, although the role of TLR within CL remains unknown. Thus, the objectives of 36 
this study were to characterize TLR mRNA expression in the CL during the estrous cycle 37 
and in pregnancy day 30-50, and to examine the role of TLR signaling in luteal cells. 38 
Corpora lutea were collected at various stages of the cycle and pregnancy and analyzed 39 
for TLR and cytokine mRNA expression. In addition, luteal cells were cultured with the 40 
TLR4 ligand (lipopolysaccharide, LPS) for 24 h to evaluate the role of TLR4 in 41 
regulating luteal function. Toll-like receptors 1, 2, 4, 6, tumor necrosis factor alpha 42 
(TNF), interferon gamma (IFNG), and interleukin (IL)12, mRNA expression was greatest 43 
in regressing CL compared with earlier stages (P<0.05), whereas no change was observed 44 
for IL6 mRNA expression. Cytokine mRNA expression in cultured luteal cells was not 45 
altered by LPS. Based on these data, one or more of the TLRs found within the CL may 46 
play a role in luteolysis, perhaps via pro-inflammatory cytokine mRNA expression.  47 
 48 
Keywords: Toll-like Receptors, Corpus Luteum, Cytokines, Luteal Immune Response 49 
  50 
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Introduction:  51 
Understanding the complex molecular regulatory mechanisms involved in the 52 
maintenance or regression (luteolysis) of the bovine corpus luteum (CL) is essential to 53 
the development of improved methods for enhancing reproductive efficiency of dairy 54 
cattle, especially since continued secretion progesterone by the CL is critical for 55 
embryonic survival and the successful outcome of pregnancy.  Luteolysis has been 56 
described as a pro-inflammatory event (Walusimbi and Pate, 2013), and there is strong 57 
evidence to show that the pro-inflammatory cytokines (e.g. Tumor Necrosis Factor (TNF) 58 
Interferon gamma (IFNG) and Interleukin 1 beta (IL1B)) display elevated levels of 59 
mRNA expression in bovine CL undergoing natural or prostaglandin (PG) F-2α-induced 60 
luteolysis (Petroff et al. 2001; Neuvians et al., 2004). Furthermore TNF and IFNG 61 
treatment of bovine luteal cells in vitro inhibited progesterone production in a dose 62 
dependent manner, indicating that these cytokines have luteolytic actions (Petroff et al., 63 
2001; Skarzynski et al., 2008; Walusimbi and Pate, 2013). Lastly, TNF and IFNG have 64 
been shown to act synergistically to promote luteal cell death (Petroff et al., 2001; 65 
Walusimbi and Pate, 2013). One ligand/receptor system that regulates inflammation in 66 
tissues are the Toll-like Receptors (TLR) and their ligands. In view of their involvement 67 
in promoting inflammation and our need to investigate further the control of 68 
inflammation during luteolysis in the bovine CL, we chose to examine the mRNA 69 
expression of these receptors in bovine CL throughout the estrous cycle and during 70 
pregnancy. 71 
Toll-like receptors are critical components of the innate-immune system, allowing 72 
host cells to recognize and mount an appropriate response (e.g. inflammation) to 73 
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microbial pathogens, that the host organism may encounter (Aflatoonian and Fazeli 2008; 74 
Kawai and Akira 2010). Toll-like receptors are members of the pattern recognition 75 
receptor (PRR) family that have evolved to recognize protein domains/sequences on 76 
various pathogens, which are known as pathogen-associated molecular patterns (PAMPs) 77 
(Aflatoonian and Fazeli 2008; Kawai and Akira 2010). There are currently 10 (human, 78 
bovine) or 12 (mouse) different TLR, each of which has a relatively well-defined 79 
function (Aflatoonian and Fazeli 2008; Davies et al. 2008; Kawai and Akira 2010). Toll-80 
like receptors 1, 2, 4 and 6 are associated with the plasma membrane and enable 81 
recognition of a variety of PAMPS produced by bacteria, viruses, fungi or parasites. 82 
Additionally, the lipopolysaccharide (LPS) and triacyl lipopeptides produced by gram 83 
negative bacteria such as E. coli is recognized by TLR4, and by TLR1 and TLR2 84 
heterodimers, respectfully, and diacyl lipopeptides of gram positive bacteria are 85 
recognized by TLR2 and TLR6 heterodimers (Aflatoonian and Fazeli 2008; Kawai and 86 
Akira 2010).  On the other hand, TLR3, 7 and 8 are intracellular receptors and recognize 87 
internalized bacterial or viral nucleic acids (Aflatoonian and Fazeli 2008; Kawai and 88 
Akira 2010). Little is known about the function of, or ligand for, TLR 10, but it is 89 
homologous to TLR2 and is likely a TLR2-associated receptor (Aflatoonian and Fazeli, 90 
2008). However, TLR (e.g TLR2 and 4) activation has also been shown to occur  in 91 
response to the products of normal cellular degradation, such as heat shock proteins 92 
(HSP) and high mobility group box 1 (HMGB1) proteins, and thus TLR-mediated pro-93 
inflammatory cytokine production may occur quite independently of microbial infection 94 
(Kawai and Akira, 2010). Furthermore, since luteolysis involves widespread cellular 95 
degeneration, it is likely that the regressing CL during the estrous cycle would represent a 96 
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rich source of potential endogenous ligands to activate TLRs expressed within this tissue 97 
in otherwise healthy animals. 98 
 The responses of Toll-like receptors to microbial pathogens have been studied in 99 
reproductive tissues such as the bovine uterus (endometrium) and ovary (Battaglia et al. 100 
2000; Sheldon et al. 2002; Herath et al. 2007; Davies et al, 2008; Sheldon et al., 2009). 101 
These investigators demonstrated several TLRs in the endometrium and examined their 102 
role in response to pathogens in cattle with uterine infections (e.g. endometritis, metritis 103 
or pyometra). Lipopolysaccharide (LPS), produced by E. coli, a common causative agent 104 
of uterine infections in dairy cows, binds to TLR4 on uterine epithelial cells. This induces 105 
a pro-inflammatory cascade of cytokines leading to altered prostaglandin (PG) production 106 
(increased PGE-2:PGF-2α ratio) by the uterus (Davies et al, 2008; Sheldon et al., 2009) 107 
which causes delayed luteolysis and extended cycles in animals with uterine infections 108 
(Davies et al, 2008; Sheldon et al., 2009; Saut et al., 2014). In other studies it was shown 109 
that LPS concentrations in peripheral blood (Mateus et al. 2003), and within the ovarian 110 
follicular fluid (Herath et al. 2007), are elevated in animals with uterine infections, 111 
suggesting that LPS may also have direct effects on ovarian function. Indeed, estrogen 112 
production and follicular growth is reduced in animals with uterine infections or in 113 
response to LPS infusion (Battaglia et al. 2000; Sheldon et al. 2002; Herath et al. 2007).  114 
It is also known that smaller follicles produce smaller CL with lower serum progesterone 115 
concentrations (Perry et al. 2005; Robinson et al. 2005), which may help to explain lower 116 
than normal luteal phase progesterone concentrations observed in animals with uterine 117 
infections (Sheldon et al. 2009). Furthermore, LPS has been shown to exert direct actions 118 
on the CL as shown by studies in which bovine luteal cells were cultured with increasing 119 
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doses of LPS, resulting in increased progesterone secretion (Grant et al. 2007). Taken 120 
together, these data suggest that in cows with uterine infections, microbial pathogens 121 
such as LPS, may also exert direct effects on the CL.  122 
 In view of the importance of improving our understanding about the role of 123 
cytokines and their role in the inflammatory luteolytic process, the overall goal of the 124 
current study was to examine the potential roles that TLR may have within the CL during 125 
the bovine estrous cycle versus pregnancy, with particular emphasis on their possible 126 
roles, via  pro-inflammatory actions, in the control of luteolysis. This study was designed 127 
to carry out the following Primary Objectives:  128 
1) To determine the steady state levels of mRNA expression of multiple TLR and 129 
cytokines in the bovine CL collected at different stages of the estrous cycle and 130 
pregnancy, and  131 
2) To examine the effects of LPS on cytokine mRNA expression by bovine luteal cells in 132 
culture.  133 
 134 
Materials and Methods: 135 
Tissue Collection 136 
 Ovaries were collected from a local abattoir (Martin’s Abattoir and Wholesale 137 
Meats, Godwin, NC). Approval to obtain specimens from this official establishment was 138 
granted by the North Carolina Department of Agriculture and Consumer Services Meat 139 
and Poultry Inspection Division. Corpora lutea (CL; n=51) were collected and catalogued 140 
by stage (I, II, III, IV, or Pregnant (P)) based on appearance, ovarian and reproductive 141 
tract morphology (Ireland et al. 1980). Corpora lutea collected at stage I (~days 1-4: 142 
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n=7), stage II (~days 5-10: n=11), stage III (~days 11-17: n=11), stage IV (~days 18-20: 143 
n=13), and from pregnancy (~ 30-50 days: n=7), were used for these experiments. 144 
Corpora lutea of pregnancy were confirmed by the presence of embryos in the uterus. 145 
Stage of pregnancy was estimated by conceptus size or crown-rump length measurement 146 
(by Dr. Peter Farin). Following collection, luteal tissues were frozen at -80˚C until 147 
analysis for mRNA or progesterone concentrations. Additional mid-stage (stage II; n=6) 148 
CL were collected and placed into ice-cold Hams F-12 media (Gibco, Invitrogen 149 
Corporation, Carlsbad, CA, USA) during transport to the laboratory to be dissociated for 150 
culture experiments. 151 
Dissociation of corpora lutea 152 
 Corpora lutea were collected and dissociation of luteal tissue was performed 153 
according to Pate (1993). Luteal tissue was minced and placed in 24 mM HEPES-154 
buffered Ham’s F-12 culture medium (Gibco, Invitrogen) containing 0.5% BSA (Sigma–155 
Aldrich, St. Louis, MO, USA), 20 µg/ml gentamicin (Gentamicin Reagent Solution; 156 
Invitrogen), and 2000 U/g tissue collagenase type I (Worthington Biochemical 157 
Corporation, Lakewood, NJ, USA). Pate (1993) demonstrated that this method of luteal 158 
cell isolation results in highly enriched populations of small and large luteal cells. 159 
Smaller cell types, endothelial cells, fibroblasts, immune cells, are removed during the 160 
slower speed centrifugation process (Pate 1993; Poole and Pate, 2012).  Enrichment of 161 
small and large luteal cells as previously described (Pate, 1993; Poole and Pate, 2012) 162 
was confirmed in this set of experiments.  Following dissociation, luteal cells were re-163 
suspended in Ham’s F-12 culture medium and cell viability was determined via standard 164 
viability stain (trypan blue; Sigma–Aldrich). Cells were placed in a 0.5% trypan blue 165 
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solution, and counted on a hemacytometer according to Pate (1993) with cell viability 166 
routinely > 80% live cells. 167 
Luteal cell culture 168 
 Luteal cells (1.0x106 cells/ml) were plated to approximately 75% confluency in 169 
24 well plates in 24 mM HEPES-buffered Ham’s F-12 culture medium (Gibco, 170 
Invitrogen) containing 5% FCS (Sigma–Aldrich), 20 µg/ml gentamicin (Gentamicin 171 
Reagent Solution; Invitrogen) and incubated for 24 h at 37°C and 5% CO2 in air. After 172 
24 hr, media was replaced to remove dead cells and debris. Luteal cells were treated with 173 
LPS (TLR ligand tested; cat # L3024; Sigma–Aldrich) at 0, 0.01, 0.1, 1 μg/ml 174 
concentrations and were incubated at 37°C and 5% CO2 in air, for additional 24 hours. 175 
These LPS doses have been shown to be effective in increasing progesterone secretion by 176 
bovine luteal cells in culture (Grant et al. 2007). After culture, media were removed and 177 
luteal cells were harvested to quantify cytokine mRNA by quantitative PCR (qPCR). 178 
Culture experiments were repeated a total of three times using CL from different animals. 179 
Total RNA extraction and PCR 180 
A. RNA Extraction and semi-quantitative PCR - bovine CL whole tissue samples 181 
RNA was extracted from luteal tissue (approximately 100 mg) using 1ml of 182 
TRIzol (Sigma–Aldrich) and homogenization as described by Crosier et al., (2002). 183 
Following RNA isolation, RNA pellets were allowed to dry at room temperature for 5 184 
minutes and were then dissolved in nuclease free diH2O (Sigma–Aldrich) in volumes 185 
ranging from 10-60 µl based on pellet size. The concentration of RNA, and the 260nm : 186 
280nm OD ratio, were determined by Nanodrop 2000 Spectrophotometer (Thermo 187 
Scientific, Waltham, MA, USA). RNA samples were then subjected to DNase treatment 188 
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followed by cDNA synthesis and semi-quantitative PCR as described previously (Crosier 189 
et al. 2002). For optimum synthesis efficiency, 1 µg of RNA was reversed transcribed in 190 
a total volume of 20 µl per reaction in accordance with manufacturers’ recommendations. 191 
RNA was determined to be of high quality based on a 260:280 ratio of 1.8 or more, and 192 
this was confirmed by the presence of clear 28S and 18S rRNA bands on denaturing 193 
agarose gels stained with ethidium bromide. Primers for this procedure were synthesized 194 
based upon the published GenBank sequences to produce the expected product sizes (see 195 
Table 1). All primers were validated for semi-quantitative (sq) RT-PCR by running each 196 
primer at 20, 25, 30, 35 and 40 cycles and choosing a cycle number that corresponded to 197 
the linear range of amplification (36 cycles for all primer sets, except for the 198 
housekeeping gene, Beta Actin (ACTB) which was 33 cycles).  Once primers were 199 
validated, sq RT-PCR was carried out using 2 µl of the cDNA product and the Taq PCR 200 
Mastermix® Kit (Qiagen Sciences, Valencia, CA, USA). Thermocycler conditions were 201 
as follows: 3 minute initial denaturation 94°C, followed by 33 or 36 cycles: denaturation, 202 
30 seconds 94°C; annealing, 1 minute 50°C; extension, 1 minute 72°C; followed by a 5 203 
minute 72°C final extension. Amplicons were separated on 2% agarose gels and stained 204 
with ethidium bromide. Signal intensities were quantified using Lab-Works imaging 205 
system (UVP Imagining Company, Upland, CA, USA).  Values were calculated as the 206 
ratio of amplicon band intensity/ACTB band intensity; ACTB was used as a 207 
housekeeping gene since its levels of mRNA expression did not vary with stage of 208 
estrous cycle.  209 
B. RNA Extraction and quantitative (Q)-PCR - bovine CL whole tissue and cell culture 210 
samples 211 
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 Total RNA was extracted and purified from luteal tissues at various stages of the 212 
estrous cycle/pregnancy and the cultured luteal cells, using the RNeasy® mini kit 213 
(Qiagen Sciences, Valencia, CA, USA) according to manufacturer’s recommendations. 214 
DNase treatment (Turbo DNA-free kit, Life Technologies, Carlsbad, CA, USA) was 215 
performed and RNA concentrations and purity determined using the Nanodrop 2000 216 
Spectrophotometer (Thermo Scientific, Waltham, MA, USA). Random-primed, reverse-217 
transcribed (RT) cDNA synthesis in 20 µl reactions were performed using the iScript 218 
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) according to manufacturer’s 219 
recommendations. For optimum synthesis efficiency, 1 µg of RNA was reversed 220 
transcribed in a total volume of 20 µl per reaction in accordance with manufacturers’ 221 
recommendations.  Forward and reverse primers directed toward Bos taurus TLR 1, 2, 4 222 
and 6, TGFB, IFNG, TNF, IL6 and IL12A (Table 2; Integrated DNA Technologies, 223 
Coralville, IA, USA) were designed specifically for Q-PCR.  Final concentrations (300 224 
nM) of the forward and reverse primers were determined for each primer pair based upon 225 
optimal amplification efficiency (> 95%).  Following the RT reaction, Q-PCR was 226 
performed on the LightCycler 480 II (Roche Diagnostics, Indianapolis, IN, USA) using 227 
the SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) with 228 
2 µl of the cDNA product in a 20 µl reaction volume under the following conditions: 95 229 
oC for 5 min, 40 cycles of 94 oC for 30 s, 57 oC for 45 s, and 72 oC for 60 s, followed by 230 
an extra elongation of 5 min at 72 oC. Annealing temperature was optimized for each 231 
primer set. Primers were optimized using a temperature gradient from 51o to 61˚C and 232 
checked for specificity based on the appearance of a single band via 1.2% agarose gel in 233 
1X TAE buffer. Optimal annealing temperature for all primers was 57°C with a 300 nM 234 
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primer concentration. Melting curves were generated for each run. The Q-PCR 235 
amplification products were electrophoretically separated on 1.5% agarose gels and 236 
visualized with ethidium bromide under UV light to ensure a specific band corresponded 237 
to the size of the expected cDNA fragment. Specific bands were extracted and purified 238 
using QIAquick gel extraction kit (Qiagen Sciences, Valencia, CA, USA). Following 239 
extraction, Q-PCR products were sequenced to confirm product specificity. A control 240 
sample that was not reverse transcribed was used to confirm that the product obtained 241 
was not amplified from genomic DNA. The Ct (the cycle number at which the 242 
fluorescence exceeds a threshold level) was determined for each reaction (run in 243 
triplicate) using the LightCycler 480 software and quantification was accomplished by 244 
normalization of Q-PCR data for each TLR and cytokine to that of ribosomal protein L19 245 
(RPL19) RNA (housekeeping gene), using the ∆∆Ct method (Livak and Schmittgen 246 
2001). Ribosomal protein L19 was shown to be a constitutively expressed gene across all 247 
CL from different stages of the cycle and pregnancy. Q-PCR data from the luteal cell 248 
cultures studies were expressed as fold-difference compared with the control treatment (0 249 
µg/ml of LPS).  250 
Progesterone Radioimmunoassay  251 
 The method for the extraction and assay of CL progesterone concentrations was 252 
adapted from previously published methods (Estill et al. 1995; Garverick et al., 1985). 253 
Briefly, approximately 100 mg of luteal tissue was immersed in 10ml of cold 100% 254 
ethanol and homogenized. After centrifugation, the ethanol extract was dried under 255 
nitrogen and re-constituted in radioimmunoassay buffer (phosphate buffered saline plus 256 
0.1% gelatin; PBS-gel; Estill et al, 1995). CL samples and progesterone standards (25-257 
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2000 pg/ml) were assayed in duplicate using the Coat-a-count RIA kit (Coat-a-count, 258 
Diagnostic Products Corporation, Los Angeles, CA, USA) following the manufacturers 259 
instructions (Richards et al., 1994; Estill et al., 1995). All samples were run in a single 260 
assay and the intra-assay coefficient of variation was 6.3%. The sensitivity of this assay 261 
was 10 pg progesterone per tube (Richards et al., 1994). This assay has also been 262 
validated in our laboratory for use with bovine serum in a single assay (Whisnant and 263 
Burns, 2002; Lyons et al., 2016). Data are reported as nanograms of progesterone/mg 264 
luteal tissue. 265 
Statistical Analysis:  266 
          All statistical analyses were performed using the mixed model of SAS (Statistical 267 
Analysis System Institute, Cary, NC, USA). mRNA expression data were log-268 
transformed and analyzed using covariate analysis, with RPL19 as the covariate for Q-269 
PCR and ACTB as the covariate for semi-quantitative PCR. One-way ANOVA was 270 
performed to determine differences among stages of luteal development for progesterone 271 
concentrations. In addition, a correlation analysis (PROC CORR) was conducted to 272 
determine the relationship between the mRNA expression of TLR and pro-inflammatory 273 
cytokines within bovine luteal tissue. Cell culture experiments were independently 274 
replicated with cells from different animals a minimum of three times unless otherwise 275 
stated. Additionally, the cell culture experiment was analyzed for linear, quadratic, and 276 
cubic relationships using a PROC GLM with orthogonal contrast for respective 277 
relationships. Differences were considered significant at p < 0.05, and a statistical 278 
tendency was declared when 0.05<p<0.1. 279 
Results: 280 
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Progesterone Concentrations within bovine CL: 281 
Whole tissue CL progesterone concentrations were significantly decreased to 6.5 282 
+ 2.2 ng/mg in stage IV CL, from ~ 30-40 ng/mg observed in CL from stages I, II, III, 283 
and in pregnancy (p<0.001). These CL progesterone concentrations are in agreement with 284 
those published by Garverick and colleagues (Garverick et al., 1985) in the bovine CL, 285 
who used a similar CL extraction procedure for progesterone.  286 
TLR 1, 2, 4 and 6 mRNA expression: 287 
The steady state mRNA expression levels of Toll-like receptors 1, 2, 4 and 6 288 
mRNAs were examined in whole tissue CL samples via Q-PCR (Fig. 1). Toll-like 289 
receptor 1 mRNA expression was significantly increased in stage IV compared to stages 290 
I, II and III (p<0.01). Similar stage dependent profiles were seen for TLR2, TLR4 and 291 
TLR6 with a significantly increased at stage IV compared to stages I, II, III, and 292 
pregnancy (p<0.01; p<0.05; p<0.05; respectfully). There was also a tendency for 293 
pregnancy to show increased TLR6 mRNA expression over stage II (p< 0.1).  294 
TLR3, 7, 8 and 10, mRNA expression:  295 
Analysis of steady state mRNA levels of TLR3, 7, 8 and 10 was carried out by 296 
semi-quantitative (sQ) PCR, and the data are summarized in Table 3. No significant 297 
differences were observed between the stages of the cycle or pregnancy for any of these 298 
TLRs. TLR3 mRNA expression at stage IV tended to be lower (p< 0.1) than stage III. 299 
TLR8 mRNA expression tended to be lower in pregnancy compared to stage IV (p< 0.1).  300 
MD2, CD14 and CD45 mRNA expression:  301 
An examination of the expression levels of MD2, CD14 and CD45 mRNAs was 302 
also carried out by semi-quantitative (sQ) PCR (Table 3). Lymphocyte antigen (MD2) 303 
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and CD14 were examined since they represent critical components of TLR4 signaling. 304 
Expression of MD2 was signficantly increased at stage III compared to stages I, II, IV 305 
and pregnancy (p<0.05). CD14 showed a similar increase (significant) at stage III 306 
compared to stage IV (p<0.01). Cluster of Differentiation (CD) 45 (non-specific marker 307 
of leukocytes) mRNA expression was significantly increased (p=0.01) from stage I to 308 
stage III and there was a tendency (p<0.1) for stage III to be increased compared to stage 309 
II. Expression of CD45 at Stage IV was significantly decreased compared to stages II, III, 310 
and pregnancy (p<0.05). 311 
Cytokine mRNA expression:  312 
Interferon gamma, IL6, IL12 and TNF mRNA expression was also examined in 313 
whole tissue CL samples by Q-PCR (Fig. 2). IFNG was significantly increased at stage 314 
IV compared to stages I, II, III, and pregnancy (p<0.05). Interleukin 12 mRNA 315 
expression displayed a similar profile with a significant increase observed at stage IV vs. 316 
stages I, II, III, and pregnancy (p<0.01). Tumor necrosis factor mRNA expression also 317 
showed a significant increase at stage IV compared with stages I, II, III, and pregnancy 318 
(p<0.01). The cytokine IL6 tended to be decreased in pregnancy compared to stage I 319 
(p<0.1) but showed no other stage dependent changes. There was no stage-dependent 320 
differential expression seen for TGFB mRNA expression (Fig. 2). An analysis of 321 
correlation between TLRs and proinflammatory cytokines (IFNG, IL6, 12, and TNF) 322 
mRNA expression in bovine CL tissue revealed a significant positive correlation (p < 323 
0.001) between TLR1, 2, 4, and 6 and IFNG, IL12, and TNF mRNA expression (Table 4 324 
and Fig. 3). No significant correlations were found between TLR1, 2, 4, and 6 and IL6 325 
(Table 4).  326 
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Cytokine mRNA expression in bovine luteal cells treated with LPS in culture  327 
Luteal cells were dissociated and cultured for 24h with LPS (0, 0.01, 0.1, 328 
1 µg/ml). Cytokine (TNF, TGFβ, IFNG, IL6, and IL12) mRNA expression did not 329 
significantly differ in response to increasing LPS doses (p>0.05; Fig. 4), even though 330 
there were numerical increases observed in IFNG and IL6 mRNA expression with 331 
increasing LPS dose. Additional analyses to test for a linear, quadratic, or cubic 332 
relationships for cytokine mRNA expression relative to LPS doses were carried out, but 333 
did not show any significance (p>0.05). 334 
 335 
Discussion:  336 
The major focus of this study was to improve our understanding of role of TLR in 337 
the pro-inflammatory/luteolytic process during the estrous cycle in normal animals. 338 
However, the data described here may also be viewed from the perspective that in the CL 339 
of cows with uterine infections, TLRs may also respond to the direct actions microbial 340 
agents, leading to inappropriate inflammatory pathways that may have adverse impacts 341 
on the CL, reproductive cyclicity and pregnancy in these animals. 342 
The studies described above provide compelling evidence for the expression of 343 
mRNAs for 8 different TLRs (i.e. TLR1, 2, 3, 4, 6, 7, 8 and 10) within the bovine CL by 344 
PCR analysis. TLR1-TLR10 mRNAs were also found to be expressed in bovine follicles 345 
raising the possibility that TLR mRNA expression continues following ovulation and 346 
during luteinization of the follicle into a fully functioning CL (Herath et al. 2007; Price et 347 
al. 2013).  348 
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Stage IV CL are essentially CL undergoing luteal regression as confirmed by the 349 
reduced CL progesterone concentrations seen at this stage, which prompts us to suggest 350 
that the increase of TLR1, 2, 4 and 6 mRNA expression (Figure 1) may be associated 351 
with, or in some way involved in, the process of luteolysis potentially through the up-352 
regulation of pro-inflammatory cytokines (IFNG, TNF and IL12; Figure 2). The 353 
correlation data (Table 4 and Fig. 3) showing significant positive correlations between 354 
TLR1, 2, 4 and 6 mRNAs and these cytokines, support the notion that these TLRs may 355 
function to promote pro-inflammatory cytokine secretion during luteolysis in the cow. 356 
Luteolysis has been described as a pro-inflammatory event (Walusimbi and Pate, 2013), 357 
and the significantly elevated mRNA expression of pro-inflammatory cytokines TNF, 358 
IFNG and IL12 mRNA observed in this study in stage IV CL, support this notion. 359 
Numerous studies have demonstrated that TNF and IFNG act as luteolytic, and 360 
(cooperatively) as cytotoxic, agents within the bovine CL (Petroff et al. 2001; Skarzynski 361 
et al. 2008; Walusimbi and Pate, 2013), and these cytokines have been shown by others 362 
to display elevated mRNA expression in regressing bovine CL (Petroff et al. 2001). 363 
Furthermore, Neuvians and colleagues (Neuvians et al., 2004) have shown that PGF2α 364 
treatment of cows increased TNF, IFNG, and IL1B mRNA expression, and that TNF and 365 
IFNG treatment of bovine luteal cells in vitro inhibited progesterone production in a dose 366 
dependent manner. Interleukin 12 (IL12), which was also elevated in regressing CL in 367 
our studies, is a classical pro-inflammatory cytokine, and was shown to promote natural 368 
killer cell differentiation, leading to increased IFNG mRNA expression (Yang et al. 369 
2011). Since in our studies both IL12 and IFNG were elevated, a similar relationship may 370 
also exist in the bovine CL. It is worth considering what ligands might be involved in 371 
17 
 
activating these TLRs in the bovine CL of a normal healthy animal, in the absence of 372 
ligands (e.g. LPS) generated by bacteria or viruses. It has been suggested that the 373 
breakdown products of luteal tissue and dead or dying cells, such as those of the 374 
extracellular matrix, heat-shock proteins and high mobility group box 1 (HMGB1) 375 
proteins, may activate TLR (e.g TLR2 and 4) and thus promote pro-inflammatory 376 
cytokine production (Kawai and Akira, 2010). Since stage IV represents regressing (i.e. 377 
degenerating) CL, it is likely that this would represent a rich source of potential 378 
endogenous ligands to activate TLRs expressed within this tissue.  379 
The results presented here for TLR 2 and 4 are consistent with a recent publication 380 
showing that these two TLR are expressed in the bovine CL, and that their mRNA 381 
expression was increased in CL collected at mid and late stages of the estrous cycle, 382 
compared with those collected during the early cycle (Luttgenau et al. 2016). These 383 
investigators were also able to demonstrate the mRNA expression of TLR 2 and 4 at the 384 
protein level using immunohistochemistry, and they observed immunoreactivity in both 385 
endothelial and luteal cells, providing some critical insights into the cellular location of 386 
these TLRs (Luttgenau et al. 2016).  387 
Even though it is clear that TLR 2 and 4 are expressed on luteal and endothelial 388 
cells in non-regressing CL (Luttgenau et al. 2016), it is possible that as luteolysis 389 
proceeds, at least some of the increased TLR2 and 4 mRNA’s observed in the regressing 390 
(stage IV) bovine CL described above, may be associated with increased immune cell 391 
(e.g. macrophages, T-cells, and neutrophils) infiltration into the CL (Walusimbi and Pate 392 
2013). In the present study, CD45, which is a common leukocyte marker (Aflatoonian 393 
and Fazeli 2008; Kawai and Akira 2010), increased at stage III (vs. stage I), but 394 
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decreased again at stage IV, while TLR1, 2, 4 and 6 mRNAs were at their maximal levels 395 
in CL undergoing luteal regression (stage IV). Thus, while the increased mRNA 396 
expression of CD45 from the developing CL (stage I) to a fully functional CL (stage III) 397 
may be explained by the increased infiltration of immune cells into the CL during this 398 
period, the decline in CD45 mRNA observed in stage IV CL, is difficult to explain since 399 
this is a time when immune cell infiltration would be maximal (Walusimbi and Pate 400 
2013).  401 
Further evidence to indicate that TLR4 in bovine CL is functional, comes from 402 
our data showing that two critical components of TLR4 signaling in response to its ligand 403 
LPS, namely MD2 and CD14, were also expressed at mRNA level in the bovine CL. 404 
MD2, which is a TLR4 co-receptor, is located found on the external cell membrane and 405 
aids in the binding of ligand (e.g. LPS) to the extracellular domain of the TLR4 dimer 406 
(Hirata et al. 2005). Cluster of differentiation (CD) 14 also plays a role in the binding of 407 
LPS to TLR4, and is an essential component of the functional TLR4 complex (Kawai and 408 
Akira 2010). The mRNA expression of CD14 and MD2 mRNAs seen in fully functional 409 
CL (stage III) were significantly elevated compared with early (stage I) and late (IV) 410 
stages, suggesting that these components are expressed prior to the elevated mRNA 411 
expression of TLR4 seen at stage IV, to prepare the TLR4-receptor-signaling complex for 412 
a critical role in luteal regression.  413 
It should be noted that TLR2 and 4, and all cytokine mRNAs were found to be 414 
decreased in pregnancy vs. stage IV CL. The general pattern of reduced pro-415 
inflammatory TLR and cytokine mRNA expression profiles during gestation may be 416 
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needed to prevent luteolysis, and ensure sufficient progesterone secretion to maintain 417 
pregnancy and embryo survival (Aflatoonian and Fazeli 2008).  418 
Even though the anti-inflammatory cytokine TGFB was expressed in the bovine 419 
CL, it did not show a differential mRNA expression patterns based on CL stage. TGFB 420 
may have a role in the CL throughout the estrous cycle and pregnancy to counter any 421 
unexpected inflammatory signals that may threaten CL maintenance, and thus may play a 422 
critical role in the ongoing regulation of luteal lifespan. Alternatively, since PGF2α 423 
treatment of bovine luteal endothelial cells induced the mRNA expression of TGFB, it 424 
has been suggested that TGFB may play a role in disassembly of the microvasculature 425 
during luteal regression (Maroni and Davis 2011).  426 
In the current study, the intracellular TLRs (TLR3, TLR7, and TLR8) did not 427 
display significantly different mRNA expression profiles at different stages of the estrous 428 
cycle or pregnancy. These TLRs recognize viral or bacterial nucleic acids (Kawai and 429 
Akira 2010), and given the location of the CL, the likelihood of luteal cells coming into 430 
direct contact with bacteria or viruses is probably very small. Thus, the function of these 431 
TLR within the CL is unknown and warrants further investigation. However, it has been 432 
suggested that DNA arising from dead or dying cells may bind these TLR and activate 433 
their intracellular pathways (Kawai and Akira 2010). Thus since luteolysis results in 434 
wholesale death of multiple cells types, these TLR may also play an important role within 435 
the regressing CL.  436 
In the culture studies, we used dissociated bovine luteal cells from mid-cycle 437 
(stage II) CL to examine a functional role of TLR4, using its ligand LPS, on cytokine 438 
production, as a model for the pro-inflammatory response seen during luteolysis. 439 
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However, multiple analyses of linear, quadratic, and cubic relationships between different 440 
LPS treatment doses were unable to reveal any statistically significant changes in 441 
cytokine mRNA expression, even though some numerical increases in IFNG and IL6 442 
mRNA expression were evident. There are several possible explanations for the apparent 443 
lack of an effect of LPS on luteal cell cytokine mRNA expression. Firstly, while the CL 444 
used for these studies were stage II, to maximize the yield of viable luteal cells and their 445 
survival during the culture, TLR4 levels (mRNA expression) were quite low at these 446 
stages, and only increased in stage IV CL. It is possible that while a more robust response 447 
to LPS may be observed in stage IV cells in vitro, obtaining sufficient viable and culture-448 
healthy cells to carry out this study would probably represent an insurmountable 449 
challenge. Secondly, the CL is a heterogeneous tissue composed of multiple cell types 450 
such as large luteal cells, small luteal cells, fibroblasts, endothelial cells and immune cells 451 
(Skarzynski et al. 2008), many of which may express TLR4 and be targets for LPS 452 
(Aflatoonian and Fazeli, 2008; Kawai and Akira 2010; Luttgenau et al. 2016). Variations 453 
in the viability or proportion of any of these cell types could contribute to the variability 454 
seen in these cultures, which did show some evidence of a numerical increase in IFNG 455 
and IL6 at the highest dose, but were not significant. It is worth noting that in recent 456 
studies, the effects of LPS on bovine (mid-cycle) CL function were examined in vivo, 457 
and decreased enzymes associated with progesterone secretion and elevated IL1B and 458 
TNF mRNA expression were observed (Luttgenau et al. 2016), suggesting that the bovine 459 
luteal TLR4 receptor acts as a functional receptor. 460 
 In conclusion, we have presented evidence for the mRNA expression of several 461 
TLR, TLR4 accessory proteins (CD14 and MD2) and cytokine mRNAs in bovine CL, 462 
21 
 
which appear to be maximal in mid (stage III; CD14 and MD2) and late (stage IV; TLR 463 
and cytokines) CL. These findings suggest an involvement of one or more of the TLR in 464 
the process of luteolysis, and perhaps in the increased mRNA expression of pro-465 
inflammatory cytokines, which also play a role in luteolysis. Finally, in view of the 466 
prevalence of infectious diseases such as uterine infections (Sheldon et al. 2009) and 467 
mastitis (Barker et al.1998) in dairy cattle, the data presented in this manuscript also raise 468 
the possibility that TLR on the bovine CL may mediate adverse effects of infectious 469 
pathogens, leading to infertility or sub-fertility.  470 
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FIGURE LEGEND: 579 
Table 1: Primer Sequences for semi-quantitative PCR 580 
Table 2: Primer Sequences for quantitative real-time PCR 581 
Table 3: mRNA expression, via semi-quantitative PCR, of various toll like receptors 582 
(TLR3, 7, 8, and 10) and their co-activators, Lymphocyte antigen (MD2) and Cluster 583 
of Differentiation (CD) 14, and 45, at various stages of luteal development (I = days 584 
1-4: n=7, II = days 5-10: n=11, III = days 11-17: n=11, IV = days 18-20 of the estrous 585 
cycle: n=13, and P = pregnancy: n=9). Data are represented as least squared means± 586 
SEM and different letters within a row indicate significant differences (P<0.05), 587 
whereas * within a row indicates statistical tendencies (0.1<P>0.05).  588 
 589 
Table 4: Correlation table between toll like receptors (TLR) 1, 2, 4 and 6 mRNA 590 
expression and proinflammatory cytokines, interferon gamma (IFNG), interleukin (IL) 6, 591 
12, and tumor necrosis factor alpha (TNF), mRNA expression. * indicates statistically 592 
significant correlations (P<0.001). 593 
 594 
Figure 1: Toll like receptor (TLR)1, 2, 4 and 6 mRNA expression, via quantitative Real-595 
Time PCR, at various stages of luteal development (I = days 1-4: n=7, II = days 5-10: 596 
n=11, III = days 11-17: n=11, IV = days 18-20 of the estrous cycle: n=13, and P = 597 
pregnancy: n=9). Expression of TLR1, 2, 4 and 6 increased in the regressing CL (days 598 
18-20 of the estrous cycle) compared to other stages of the estrous cycle. Data are 599 
presented as least-square means ± SEM. Different letters within a specific gene indicate 600 
significant differences (P<0.05). 601 
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 602 
Figure 2: Interferon gamma (IFNG), Interleukin (IL) 6, 12, Transforming Growth Factor 603 
beta (TGFB) and Tumor necrosis factor alpha (TNF) mRNA expression, via quantitative 604 
Real-Time PCR, at various stages of luteal development (I = days 1-4: n=7, II = days 5-605 
10: n=11, III = days 11-17: n=11, IV = days 18-20 of the estrous cycle: n=13, and P = 606 
pregnancy: n=9). Expression of TNF, IFNG, and IL12 increased in the regressing CL 607 
(days 18-20 of the estrous cycle) compared to other stages of the estrous cycle. Data are 608 
presented as least-square means ± SEM. Different letters within a specific gene indicates 609 
significant differences (p<0.05), whereas * within a specific gene indicates statistical 610 
tendencies (0.1<p>0.05). 611 
 612 
Figure 3: Correlation between toll like receptor (TLR) 4 mRNA expression and 613 
proinflammatory cytokines, interferon gamma (IFNG), interleukin (IL) 6, 12, and tumor 614 
necrosis factor alpha (TNF), mRNA expression. Expression of TNF, IFNG, and IL12 615 
displayed a positive relationship with TLR4, whereas this relationship was not observed 616 
with IL6 mRNA expression.  617 
 618 
Figure 4: Interferon gamma (IFNG), Interleukin (IL) 6, 12, tumor necrosis factor alpha 619 
(TNF) and transforming growth factor beta (TGFB) mRNA expression, via quantitative 620 
Real-Time PCR, in luteal cells cultured in the presence of either 0, 0.01, 0.1, or 1 µg/ml 621 
Lipopolysaccharide (LPS) for 24 hours. No differences were observed in cytokine 622 
expression following treatment is increasing concentrations of LPS (n=3). Data are 623 
presented as least-square means ± SEM.   624 
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Table 1: Primer Sequences for semi-quantitative PCR 625 
Target GenBank accession no. Primer Sequence Cycle Amplicon size 
ACTB NM_173979.3 Fwd 5’ ATC GGC AAT GAG CGG TTC C-3’ 
Rev 5’ GTG TTG GCG TAG AGG TCC TTG-3’ 
33 143 
CD14 NM_174008.1 Fwd 5’ GGG TAC TCT CTG CTC AAG GAA C-3’ 
Rev 5’ CTT GGG CAA TGT TCA GCA C-3’ 
36 199 
CD45 AJ400864.1 Fwd 5’ CTC GAT GTT AAG CGA GAG GAA T-3’ 
Rev 5’ TCT TCA TCT TCC ACG CAG TCT A-3’  
36 185 
MD2 NM_001046517.1 Fwd 5’ GGG AAG CCG TGG AAT ACT CTA T-3’ 
Rev 5’ CCC CTG AAG GAG AAT TGT ATT G-3’ 
36 204 
TLR3 NM_001008664.1 Fwd 5’ GAT GTA TCA CCC TGC AAA GAC A-3’ 
Rev 5’ TGC ATA TTC AAA CTG CTC TGC T-3’ 
36 195 
TLR7 NM_001033761.1 Fwd 5’ TCT TGA GGA AAG GGA CTG GTT A-3’ 
Rev 5’ AAG GGG CTT AAG GAA TAT C-3’ 
36 205 
TLR8 NM_001033937.1 Fwd 5’ TAA CCT TCG GAA TGT CTC CAG T-3’ 
Rev 5’ GTG GGA AAT TCT GTT TCG ACT C-3’ 
36 232 
TLR10 NM_001076918.2 Fwd 5’ ATG GTG CCA TTA TGA ACC CTA C-3’ 
Rev 5’ CAC ATG TCC CTC TGG TGT CTA A-3’ 
36 239 
     
 626 
  627 
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Table 2: Primer Sequences for quantitative real-time PCR 628 
Target GenBank accession no. Primer Sequence Amplicon size 
IFNG NM_174086 Fwd 5’ GAT CTG GAT TCT GAG CCA CTA C-3’ 175 
  
Rev 5’ GCC AGG TAT AAG GTG AGA TGA G-3’ 
 IL6 NM_173923.2 Fwd 5’ CAA GGA GAC ACT GGC AGA AA-3’ 107 
  
Rev 5’ CAG TGG TTC TGA TCA AGC AAA TC-3’ 
 IL12A U14416 Fwd 5’ TCA AGC TCT GCA TCC TTC TTC-3’ 254 
  
Rev 5’ GGT TAT GAG AGA CCT CAG CAT TC-3’  
 RPL19 NM_001040516 Fwd 5’ ATC GAT CGC CAC ATG TAT CA-3’ 227 
  
Rev 5’ GCG TGC TTC CTT GGT CTT AG-3’ 
 TGFB M36271 Fwd 5’ CGT CAG CTC TAC ATT GAC TTC C-3’ 205 
  
Rev 5’ GGA CCT TGC TGT ACT GTG TAT C-3’ 
 TNF NM_173966 Fwd 5’ TCT ACT CAC AGG TCC TCT TCA G-3’ 235 
  
Rev 5’ GAT GTT GAC CTT GGT CTG GTA G-3’ 
 TLR1 NM_001046504.1 Fwd 5’ ATT TCT TGC CAC CCT ACT CTG-3’ 100 
  
Rev 5’ GTT GAG ACA TGT TGC CAA ACT C-3’ 
 TLR2 NM_174197.2 Fwd 5’ GCA CTT CAA CCC TCC CTT TA-3’ 127 
  
Rev 5’ GTT CTC CGA AAG CAC AAA GAT G-3’ 
 TLR4 NM_174198.6 Fwd 5’ TCT ACT GCA GCC AGG ATG AA-3’ 92 
  
Rev 5’ GTA GTG AAG GCA GAG CTG AAA-3’ 
 TLR6 NM_001001159.1 Fwd 5’ GAC TCT CAA GCA TTT AGA CCT CTC-3’ 146 
  
Rev 5’ GCA AGT GAG CAA TGG GTA GTA-3’ 
  629 
 630 
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Table 3:  631 
 Stage of Luteal Development  
Target I II III IV P P Value 
CD14 24.6±6.1ab 20.4±3.0ab 32.4±5.9ab 16.1±4.5a 22.5±8.2ab 0.0074 
CD45 16.7±2.1a 23.2±2.6ab 31.3±4.4b 17.5±4.0a 25.0±4.2ab 0.0036 
MD2  13.2±1.6a 10.4±1.4a 21.5±3.3b 13.0±3.1a 10.5±2.5a 0.0376 
TLR3 39.2±11.9 40.6±2.3 42.8±5.3* 26.8±2.8* 40.1±3.6 0.082 
TLR7 10.4±1.6 11.7±1.5 16.4±7.8 14.3±12.9 10.5±6.8 >0.05 
TLR8 10.9±2.2 15.5±5.0 18.6±2.3 22.8±8.0* 9.8±3.1* 0.084 
TLR10 14.4±3.2 8.3±2.9 8.7±4.2 9.3±7.0 10.1±2.7 >0.05 
       
 632 
Table 3: mRNA expression, via semi-quantitative PCR, of various toll like receptors (TLR3, 633 
7, 8, and 10) and their co-activators, Lymphocyte antigen (MD2) and Cluster of 634 
Differentiation (CD) 14, and 45, at various stages of luteal development (I = days 1-4: n=7, II 635 
= days 5-10: n=11, III = days 11-17: n=11, IV = days 18-20 of the estrous cycle: n=13, and P 636 
= pregnancy: n=9). Data are represented as least squared means± SEM and different letters 637 
within a row indicate significant differences (P<0.05), whereas * within a row indicates 638 
statistical tendencies (0.1<P>0.05).  639 
 640 
  641 
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Table 4:  642 
 Proinflammatory Cytokines 
 IFNG IL6 IL12 TNF 
TLR1 0.77* -0.02 0.75* 0.78* 
TLR2 0.71* -0.01 0.70* 0.75* 
TLR4 0.61* 0.09 0.60* 0.65* 
TLR6 0.80* 0.05 0.77* 0.80* 
 643 
Table 4: Correlation table between toll like receptors (TLR) 1, 2, 4 and 6 mRNA expression and 644 
proinflammatory cytokines, interferon gamma (IFNG), interleukin (IL) 6, 12, and tumor necrosis 645 
factor alpha (TNF), mRNA expression. * indicates statistically significant correlations 646 
(P<0.001). 647 
 648 
  649 
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Figure 1 650 
 651 
 652 
Figure 1: Toll like receptor (TLR)1, 2, 4 and 6 mRNA expression, via quantitative Real-Time 653 
PCR, at various stages of luteal development (I = days 1-4: n=7, II = days 5-10: n=11, III = days 654 
11-17: n=11, IV = days 18-20 of the estrous cycle: n=13, and P = pregnancy: n=9). Expression of 655 
TLR1, 2, 4 and 6 increased in the regressing CL (days 18-20 of the estrous cycle) compared to 656 
other stages of the estrous cycle. Data are presented as least-square means ± SEM. Different 657 
letters within a specific gene indicate significant differences (P<0.05). 658 
  659 
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Figure 2: 660 
 661 
Figure 2: Interferon gamma (IFNG), Interleukin (IL) 6, 12, Transforming Growth Factor beta 662 
(TGFB) and Tumor necrosis factor alpha (TNF) mRNA expression, via quantitative Real-Time 663 
PCR, at various stages of luteal development (I = days 1-4: n=7, II = days 5-10: n=11, III = days 664 
11-17: n=11, IV = days 18-20 of the estrous cycle: n=13, and P = pregnancy: n=9). Expression of 665 
TNF, IFNG, and IL12 increased in the regressing CL (days 18-20 of the estrous cycle) compared 666 
to other stages of the estrous cycle. Data are presented as least-square means ± SEM. Different 667 
letters within a specific gene indicates significant differences (p<0.05), whereas * within a 668 
specific gene indicates statistical tendencies (0.1<p>0.05). 669 
  670 
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Figure 3: 671 
 672 
 673 
 674 
Figure 3: Correlation between toll like receptor (TLR) 4 mRNA expression and 675 
proinflammatory cytokines, interferon gamma (IFNG), interleukin (IL) 6, 12, and tumor necrosis 676 
factor alpha (TNF), mRNA expression. Expression of TNF, IFNG, and IL12 displayed a positive 677 
relationship with TLR4, whereas this relationship was not observed with IL6 mRNA expression.  678 
 679 
 680 
 681 
  682 
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Figure 4: 683 
 684 
 685 
Figure 4: Interferon gamma (IFNG), Interleukin (IL) 6, 12, tumor necrosis factor alpha (TNF) 686 
and transforming growth factor beta (TGFB) mRNA expression, via quantitative Real-Time 687 
PCR, in luteal cells cultured in the presence of either 0, 0.01, 0.1, or 1 µg/ml Lipopolysaccharide 688 
(LPS) for 24 hours. No differences were observed in cytokine expression following treatment is 689 
increasing concentrations of LPS (n=3). Data are presented as least-square means ± SEM.   690 
 691 
 692 
 693 




